Burcon Nutrascience Advances Protein Production Strategy with ProMan Partnership
TL;DR
Burcon Nutrascience Corporation achieves significant progress in canola protein isolate production, positioning for growth in multi-billion-dollar TAM with potential in soy, pea, and canola protein markets.
Burcon partners with ProMan to acquire protein production facility, enabling control over plant-based protein products. First-year sales projected at $1M - 3M, profitability expected in 2026.
Burcon's advancements in plant-based protein production contribute to a healthier, sustainable food industry, offering alternatives for egg replacement applications and expanding market opportunities.
Burcon's collaboration with Puratos and launch of next-gen pea and canola proteins showcase innovation in plant-based protein industry, driving forward sustainable food solutions.
Found this article helpful?
Share it with your network and spread the knowledge!
Burcon Nutrascience Corporation has made substantial progress in its protein production strategy during the third quarter of 2025, highlighting key developments that could transform its market position. The company has successfully ramped up commercial production of its canola protein isolate and established a robust sales pipeline with over 100 prospective customers.
A pivotal strategic partnership with ProMan involves acquiring and operating a protein production facility, enabling Burcon to maintain a capital-light approach while gaining full production control. The facility is expected to commence production in the first half of 2025, with first-year sales projected between $1 million and $3 million, and double-digit revenue anticipated in the second year.
The company has demonstrated product innovation by launching next-generation proteins including Peazazz® pea protein and Puratein® canola protein for egg replacement applications. Furthermore, Burcon recently introduced Solatein™ sunflower protein isolate, expanding its product portfolio.
Financially, Burcon generated $0.06 million in revenues during the quarter, compared to zero revenues in the same period last year. The company reported a net loss of $1.8 million, an improvement from the previous year's $2.0 million loss. Research and development expenses decreased to $0.7 million from $1.1 million, while administrative expenses marginally increased.
The protein market presents significant opportunities, with Burcon identifying potential total addressable markets including soy protein isolate (US$70-116 million), pea protein (US$215-392 million), and canola protein (US$68-113 million). These markets represent substantial growth potential for the company.
A recent rights offering raised gross proceeds of $9.43 million, providing the company with approximately $10 million in pro-forma cash balance. This financial cushion supports continued product development and market expansion efforts. Stonegate Capital Partners values the company between $1.15 and $1.43 per share, with a midpoint of $1.27.
Curated from Reportable
